Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
VANI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.13
vs 0.04
Q4.23
N/A
-0.12
vs -0.06
Q1.24
N/A
-0.12
vs -0.18
Q2.24
N/A
-0.10
vs -0.13
Q3.24
N/A
-0.11
vs -0.13
Q4.24
N/A
-0.11
vs -0.12
Q1.25
N/A
-0.11
vs -0.12
Q2.25
N/A
-0.12
vs -0.10
Q3.25
N/A
-0.10
vs -0.11
Q4.25
N/A
-0.09
vs -0.11
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
518K vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-23%
398K vs 518K
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Return on Equity
QoQ
Q1.23
-16%
-0.16
vs -0.15
Q2.23
-20%
-0.20
vs -0.16
Q3.23
-26%
-0.26
vs -0.20
Q4.23
-29%
-0.29
vs -0.26
Q1.24
-21%
-0.21
vs -0.29
Q2.24
-22%
-0.22
vs -0.21
Q3.24
-33%
-0.33
vs -0.22
Q4.24
-34%
-0.34
vs -0.33
Q1.25
-54%
-0.54
vs -0.34
Q2.25
-145%
-1.45
vs -0.54
Institutionnal Ownership
QoQ
Q4.22
34
34
vs 25
36%
Q1.23
29
29
vs 34
-15%
Q2.23
32
32
vs 29
10%
Q3.23
32
32
vs 32
NA
Q4.23
28
28
vs 32
-12%
Q1.24
29
29
vs 28
4%
Q2.24
31
31
vs 29
7%
Q3.24
30
30
vs 31
-3%
Q4.24
32
32
vs 30
7%
Q1.25
27
27
vs 32
-16%
Quote Panel
Key Metrics
Forecast
2026-Revenue
-200%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
Morgan Stanley
initialisePrevious: Not converted
2022-12-05
Now: Underweight
Craig-Hallum
initialisePrevious: Not converted
2022-12-05
Now: Buy
EF Hutton
initialisePrevious: Not converted
2022-12-05
Now: Buy
Raymond James
initialisePrevious: Not converted
2022-12-05
Now: Market Perform
Relative Strength
VANI
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
seekingalpha.com
5 hours ago
zacks.com
9 hours ago
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
NASDAQ
Unprofitable
Unprofitable
-0.01Â ( -0.80%)
Relative Strenght
72
Volume Buzz
-68%
Earning Acce
No
Dist 52w H.
31%